| Document |
Document Title |
|
WO/2024/002279A1 |
Provided are an immunocompatible human pluripotent stem cell, a method for preparing same, and use thereof. The modified human pluripotent stem cell can be induced and differentiated into various tissues/organ cells, has very ideal immun...
|
|
WO/2024/001989A1 |
Provided are compositions for modulating molecules in a cell. Also provided are methods for modulating molecules in a cell.
|
|
WO/2024/003381A1 |
The present invention relates to hybrid polypeptides acting as dual GHSR and NPY5R agonists and their use in the treatment of cachexia or anorexia.
|
|
WO/2024/001242A1 |
A polypeptide and a use thereof are provided. The polypeptide comprises an N-terminal sequence and a C-terminal sequence, the N-terminal sequence comprising one or more repeating units, and said repeating unit comprising an amino acid se...
|
|
WO/2024/002129A1 |
A novel coronavirus heterologous trimerized chimeric antigen peptide, a polynucleotide encoding same or a nucleic acid product related to the polynucleotide, a vaccine or an immunogenic composition based on the antigen peptide or the pol...
|
|
WO/2023/246623A1 |
The present invention relates to a novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated C...
|
|
WO/2023/246885A1 |
The present disclosure relates to an antigen-binding molecule specifically binding to DLL3 and CD3, and pharmaceutical use thereof. The antigen-binding molecule can be used for treating cancers.
|
|
WO/2023/246135A1 |
The present disclosure relates to a peptide, a peptide-modified SIS membrane, a method for preparing same, and use thereof. Specifically, the present disclosure relates to an oligopeptide, a chimeric peptide containing the oligopeptide, ...
|
|
WO/2023/247781A1 |
The present invention relates to short peptides or salts thereof which can be modified with appropriate hydrophobic tails to generate amphiphilic molecules useful for the intracellular delivery of molecules of biological interest. Thus, ...
|
|
WO/2023/246325A1 |
Disclosed are a nanobody (Nb) targeting CD73, a nanobody-drug conjugate (NDC), a preparation method therefor and use thereof. The monoclonal nanobody and the corresponding NDC of the present invention can efficiently and specifically bin...
|
|
WO/2023/246004A1 |
Disclosed are a chimeric antigen receptor, a macrophage expressing same, and use. A primary protein structure of the chimeric antigen receptor comprises sequentially from the amino terminus to the carboxyl terminus: a signal peptide, an ...
|
|
WO/2023/246908A1 |
Provided are preparation and use of a chimeric antigen receptor immune cell targeting CSF1R. Specifically, provided is a chimeric antigen receptor (CAR) modified on the basis of a natural CSF1R ligand, the CAR comprising an extracellular...
|
|
WO/2023/248009A1 |
Human interleukin-2 (IL-2) cytokine fusions are provided. In particular, provided are IL-2 cytokines and IL-2 cytokine fusions that have an increased binding capacity for IL-2Rβ receptor as compared to wild-type IL-2 for use in dosing a...
|
|
WO/2023/248846A1 |
The present disclosure provides a carrier peptide fragment which has cell membrane permeability and makes it possible to introduce a target foreign substance from outside a eukaryotic cell into at least the cytoplasm of the cell. The car...
|
|
WO/2023/246853A1 |
The present invention relates to the technical field of antibodies, and specifically relates to a SARS-CoV-2-fighting humanized multivalent binding protein and a use thereof. The multivalent binding protein can effectively block the bind...
|
|
WO/2023/247754A1 |
The present invention relates to bifunctional molecules which contain a protein-of-interest binding moiety linked through a linker group to a cellular receptor binding moiety preferably a moiety which binds to the receptor sortilin encod...
|
|
WO/2023/248125A1 |
Single domain antibody fragments binding to CD117 and lipid nanoparticle conjugates associated with the antibodies and cargos of interest (e.g., a gene editing system). Also provided herein are methods of delivering the cargos to CD117+ ...
|
|
WO/2023/246928A1 |
The present invention relates to an improved GLP-1 receptor agonist, a fusion protein containing the improved GLP-1 receptor agonist, a polynucleotide encoding the fusion protein, a vector containing the polynucleotide, a cell, and the u...
|
|
WO/2023/246001A1 |
Disclosed is use of the combination of CAR-T and CAR-M in the preparation of an antitumor medicament. CAR-T is a T cell modified by a chimeric antigen receptor; the primary protein structure of the chimeric antigen receptor sequentially ...
|
|
WO/2023/246943A1 |
The present invention provides a T cell receptor-based multispecific polypeptide molecule, and specifically, provides a trispecific polypeptide molecule and a bispecific polypeptide molecule. The present invention further provides a nucl...
|
|
WO/2023/245543A1 |
The present disclosure provides human fibroblast growth factor 21 (hFGF21) fusion proteins for treating non-alcoholic fatty liver disease (NAFLD), diabetes, diabetic complications, obesity, dyslipidemia, metabolic syndrome, and/or disord...
|
|
WO/2023/241391A1 |
The present invention provides a TCR molecule binding to an SSX2 antigen and an application thereof. The TCR molecule can specifically bind to an SSX2 antigen short peptide complex AQIPEIQK-HLA A1101. Meanwhile, effector cells transducin...
|
|
WO/2023/244127A1 |
The present invention is concerned with novel CRISPR-Cas systems which are configured to detect the presence of a target nucleic acid in a sample through activation of secondary nucleases which bind and cleave a nucleic acid probe modifi...
|
|
WO/2023/240458A1 |
Provided in the present invention are a polypeptide inhibitor of foot-and-mouth disease virus and the use thereof. The amino acid sequence of the polypeptide for inhibiting or preventing foot-and-mouth disease virus is as shown in positi...
|
|
WO/2023/241653A1 |
The present invention relates to an IL-2 mutant, a fusion protein containing the IL-2 mutant, a nucleic acid encoding the IL-2 mutant or the fusion protein containing the IL-2 mutant, a vector and a host cell containing the nucleic acid,...
|
|
WO/2023/241697A1 |
The present disclosure provides a cell (e.g., AMD-associated cell, such as RPE) comprising a polypeptide capable of reversing phase separation and/or preventing the formation of drusen, a polynucleotide encoding the polypeptide, and/or a...
|
|
WO/2023/241492A1 |
The present invention relates to a VHH antibody that specifically binds to human CD318 or an antigen-binding fragment thereof, a preparation method therefor, and a use thereof. Provided are a CD318 binding molecule comprising an anti-CD3...
|
|
WO/2023/241024A1 |
Provided is a novel phase change adjusting element, a part of which comprises a multivalent phase change structural domain, and the remaining comprises at least two ligands, wherein at least one ligand is covalently connected to the part...
|
|
WO/2022/216514A9 |
Provided are methods for generating γδ T cells from induced pluripotent stem cells. Also provided are genetically engineered iPSCs, γδ T cells, CAR- γδ T cells, and methods of using the same.
|
|
WO/2023/241023A2 |
Provided in the present invention is a novel phase-change adjusting kit, comprising at least two independent components which can interact with each other to specifically drive themselves and cell surface molecules combined thereon to ge...
|
|
WO/2023/241669A1 |
Provided are a CRISPR-Cas effector protein, a gene editing system therefor, and an application. The CRISPR-Cas effector protein comprises a protein which is at least 70% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to...
|
|
WO/2023/236889A1 |
The present application relates to a multi-specific binding molecule targeting BCMA, GPRC5D and T cell receptors. Specifically, the present application discloses a BCMA-GPRC5D-CD3 multi-specific antibody, which can activate T cells while...
|
|
WO/2023/236891A1 |
The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, pharmaceutical composition comprising the same and the uses thereof.
|
|
WO/2023/236796A1 |
Provided are a CD79b humanized antibody-based chimeric antigen receptor and use thereof. The present disclosure relates to a CD79b humanized antibody -based chimeric antigen receptor, which includes an antigen binding domain, a transmemb...
|
|
WO/2023/235982A1 |
Provided herein are antibodies that specifically target integrin beta-2 and compositions comprising such antibodies for therapeutic and diagnostic applications. The antibodies comprise an integrin beta-2 binding domain comprising a heavy...
|
|
WO/2023/236913A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to immune cells targeting EpCAM and a medical use thereof. Provided is a use of immune cells in the preparation of a drug for preventing or tre...
|
|
WO/2023/236980A1 |
Provided are a pharmaceutical composition of a PVRIG/TIGIT bispecific antibody and use thereof. Specifically, provided is a pharmaceutical composition, comprising a PVRIG/TIGIT bispecific antibody and a buffer solution. The pharmaceutica...
|
|
WO/2023/173084A9 |
Methods and compositions for generating novel proteins comprise a genetically encoded macrocyclic peptide fused to an immunoglobulin Fc region, referred to as "cyclopeptibodies." Methods and compositions are provided for making cyclopept...
|
|
WO/2023/239265A1 |
The invention relates to biotechnology, immunology and virology, and more particularly to the creation of a vaccine against coronavirus infection and to a method for producing same, for producing a hybrid gene that codes for the recombin...
|
|
WO/2023/236468A1 |
Provided is an S protein variant, which does not contain a complete cytoplasmic tail domain compared to the S protein of a wild-type coronavirus. Further provided are a nucleic acid molecule encoding the S protein variant, and the use of...
|
|
WO/2023/237774A1 |
The present invention relates to a fusion protein that provides for maintenance of regulatory T-cells that are polyclonal, e.g. natural isolated antigen-specific Treg cells, and/or Treg cells generated by introduction of a nucleic acid c...
|
|
WO/2023/235971A1 |
Provided herein are antibodies to active integrin beta-2 and compositions comprising such antibodies for the treatment of a cancer, e.g., acute myeloid leukemia.
|
|
WO/2023/236954A1 |
The present invention relates to a PD-1 variant and the use thereof. Specifically, the PD-1 variant of the present invention can bind to PD-L1 with high affinity, but does not bind to one or more anti-PD-1 monoclonal antibodies, and pref...
|
|
WO/2023/238127A1 |
The present invention provides cyclic peptides, as well as methods of using the same, such as for ameliorating or treating a K63Ub-related disease in a subject in need thereof.
|
|
WO/2023/236726A1 |
Disclosed is use of a metallothionein as an immune adjuvant. The use of the metallothionein with an immunogenic antigen in the form of a fusion protein or a composition can quickly, efficiently, and permanently excite an antigen-specific...
|
|
WO/2023/230729A1 |
The present description relates to synthetic antigen receptors for use with covalent immune recruiters (CIRs) comprising an donor moiety, a covalent binding group, and a target binding domain (TBD), the synthetic antigen receptor compris...
|
|
WO/2023/232022A1 |
The present application provides a recombinant fusion protein, comprising 1) a PD-L1 antibody or an antigen-binding fragment thereof, and 2) a VEGF-binding peptide, the N-terminus of a heavy chain or a light chain of the PD-L1 antibody o...
|
|
WO/2023/231969A1 |
The present invention belongs to the field of protein engineering, and relates to a hybrid peptide formed by a chymotrypsin inhibitory peptide and insulin or an analogue thereof. The heterozygous insulin analogue can resist the degradati...
|
|
WO/2023/235648A1 |
Methods and compositions for nuclear delivery and transcriptional repression employ a cell-penetrant MeCP2 fusion protein.
|
|
WO/2023/234416A1 |
The present invention relates to a technology for facile chemical modification of only one heavy chain in an antibody structural unit (immunoglobulin unit comprising two heavy chains and optionally two light chains). More specifically, t...
|
